EGFR and neoplasm: Based on the positive results of the ADAURA study, osimertinib is currently indicated for adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R substitution mutations (Table 5).